🇺🇸 FDA
Company

Crinetics

Crinetics Pharmaceuticals

CRNX pharma USA

Quick answer

Crinetics is a pharma company (CRNX) headquartered in SAN DIEGO, CA, USA with 12 tracked pipeline programs.

Pipeline (12)

project

Atumelnant

Congenital Adrenal Hyperplasia

Phase 3 · small_molecule · active

2 trials project

Paltusotine

Carcinoid Syndrome

Phase 3 · small_molecule · active

1 trials project

Paltusotine

Acromegaly

Phase 3 · small_molecule · active

5 trials project

CRN09682

SST2-positive Neuroendocrine Neoplasms

Phase 2 · small_molecule · active

1 trials project

Randomized: 40 mg Paltusotine

Carcinoid Syndrome

Phase 2 · small_molecule · completed

1 trials project

atumelnant

Cushing Syndrome

Phase 2 · small_molecule · active

1 trials project

atumelnant (CRN04894)

Congenital Adrenal Hyperplasia

Phase 2 · small_molecule · active

2 trials project

Atumelnant

Healthy Volunteers

Phase 1 · small_molecule · active

2 trials project

CRN00808

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

CRN01941 Oral Solution

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

CRN04894 Oral Solution

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

[14C]-CRN00808

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials

Drugs (1)

drug

paltusotine hydrochloride

PALSONIFY

Patents (8)

patent

US 12280046

Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12208092

Compositions and methods for administering paltusotine to patients with hepatic

Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12134610

Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11957674

Formulations of a somatostatin modulator

Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11834462

Somatostatin modulators and uses thereof

Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11773076

Crystalline forms of a somatostatin modulator

Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11608335

Somatostatin modulators and uses thereof

Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11566015

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)